Fengyi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fengyi Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Jiayi Zhang
Shandong University of Traditional Chinese Medicine Jinan China
2 shared publications- Wenbo Wang
Shandong University of Traditional Chinese Medicine Second Affiliated Hospital, Jinan, 250001, People's Republic of China
2 shared publications Xin Wang
Shandong University of Traditional Chinese Medicine Jinan China
2 shared publicationsYufeng Zhang
Shandong University of Traditional Chinese Medicine Jinan China
2 shared publications- Yujie Li
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine Jinan China
2 shared publications Jingjing Pan
Shandong University of Traditional Chinese Medicine Jinan China
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in Phytotherapy Research
Astragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage
Metabolic dysfunction–associated fatty liver disease (MAFLD) is associated with hepatic lipid accumulation, inflammation, and hepatocyte apoptosis. Astragaloside IV (AS‐IV) has been reported to regulate lipid metabolism, but its effects on hepatocyte apoptosis in MAFLD remain unclear. We investigated the effects of AS‐IV in db/db mice and free fatty acid (FFA)–treated HepG2 cells using biochemical assays, histological staining, measurements of inflammatory markers and reactive oxygen species, and apoptosis assays. Network pharmacology and molecular docking were used to identify candidate targets, followed by analyses of CASP3 and PARP1 expression and cleavage and CASP3 overexpression experiments. AS‐IV reduced hepatic and cellular triglyceride accumulation, inflammatory markers, and hepatocyte apoptosis, and improved liver histology and serum markers of liver injury in db/db mice. These effects were accompanied by reduced CASP3 activation and PARP1 cleavage. In HepG2 cells, AS‐IV also attenuated the changes associated with CASP3 overexpression. Together, these findings suggest that suppression of CASP3‐associated PARP1 cleavage may contribute to the protective effects of AS‐IV in these experimental models of MAFLD.
- 13 November 2026
- Published by Wiley in Phytotherapy Research
Open AccessAstragaloside IV Mitigates Hepatocyte Apoptosis in Metabolic Dysfunction–Associated Fatty Liver Disease Through Inhibition of CASP3 ‐Dependent PARP1 Cleavage
Metabolic dysfunction–associated fatty liver disease (MAFLD) is associated with hepatic lipid accumulation, inflammation, and hepatocyte apoptosis. Astragaloside IV (AS‐IV) has been reported to regulate lipid metabolism, but its effects on hepatocyte apoptosis in MAFLD remain unclear. We investigated the effects of AS‐IV in db/db mice and free fatty acid (FFA)–treated HepG2 cells using biochemical assays, histological staining, measurements of inflammatory markers and reactive oxygen species, and apoptosis assays. Network pharmacology and molecular docking were used to identify candidate targets, followed by analyses of CASP3 and PARP1 expression and cleavage and CASP3 overexpression experiments. AS‐IV reduced hepatic and cellular triglyceride accumulation, inflammatory markers, and hepatocyte apoptosis, and improved liver histology and serum markers of liver injury in db/db mice. These effects were accompanied by reduced CASP3 activation and PARP1 cleavage. In HepG2 cells, AS‐IV also attenuated the changes associated with CASP3 overexpression. Together, these findings suggest that suppression of CASP3‐associated PARP1 cleavage may contribute to the protective effects of AS‐IV in these experimental models of MAFLD.
- Open Access
- 8 February 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (2) , e0298070
Small dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization
Background: Patients with T2DM often suffer from CVD-related complications, significantly impacting morbidity and mortality rates. The upsurge in CVD prevalence among them is partly linked to sd LDL particles. Understanding the mechanisms behind elevated sd LDL levels is critical for preventing and managing cardiovascular complications in diabetes. Methods: MR was employed to identify instrumental variables and establish causality, exploring underlying mechanisms. Results: Notably, T2DM itself, insulin resistance, and fasting glucose seemingly do not directly impact sd LDL levels. Instead, the presence of T2DM or insulin resistance, leading to reduced HDL cholesterol or elevated TG levels, directly contributes to subsequent sd LDL increases, indicating a comprehensive mediating effect. While LDL cholesterol levels correlate positively with sd LDL, they appear unaffected by T2DM or insulin resistance. Importantly, hypertension induced by T2DM or insulin resistance exhibits a positive effect on sd LDL reversal. Unlike T2DM or insulin resistance, blood glucose levels show no significant impact on all processes. Conclusions: It is hoped that these insights might influence the treatment of patients with diabetes and the management of blood parameters in clinical practice. Examining the effect of T2DM or insulin resistance on sd LDL within HDL cholesterol and triglycerides pathways might provide valuable insights for targeted cardiovascular treatments. Additionally, the study’s exploration of the potential positive effects of elevated blood pressure on sd LDL reversal may introduce novel considerations for blood pressure management in patients with diabetes.
- 8 February 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (2) , e0298070
Open AccessSmall dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization
Background: Patients with T2DM often suffer from CVD-related complications, significantly impacting morbidity and mortality rates. The upsurge in CVD prevalence among them is partly linked to sd LDL particles. Understanding the mechanisms behind elevated sd LDL levels is critical for preventing and managing cardiovascular complications in diabetes. Methods: MR was employed to identify instrumental variables and establish causality, exploring underlying mechanisms. Results: Notably, T2DM itself, insulin resistance, and fasting glucose seemingly do not directly impact sd LDL levels. Instead, the presence of T2DM or insulin resistance, leading to reduced HDL cholesterol or elevated TG levels, directly contributes to subsequent sd LDL increases, indicating a comprehensive mediating effect. While LDL cholesterol levels correlate positively with sd LDL, they appear unaffected by T2DM or insulin resistance. Importantly, hypertension induced by T2DM or insulin resistance exhibits a positive effect on sd LDL reversal. Unlike T2DM or insulin resistance, blood glucose levels show no significant impact on all processes. Conclusions: It is hoped that these insights might influence the treatment of patients with diabetes and the management of blood parameters in clinical practice. Examining the effect of T2DM or insulin resistance on sd LDL within HDL cholesterol and triglycerides pathways might provide valuable insights for targeted cardiovascular treatments. Additionally, the study’s exploration of the potential positive effects of elevated blood pressure on sd LDL reversal may introduce novel considerations for blood pressure management in patients with diabetes.